Dabur India Q3 net profit up 13 percent to Rs 333 crore

Published On 2018-02-02 04:00 GMT   |   Update On 2018-02-02 04:00 GMT

New Delhi: Dabur India reported 13 percent rise in consolidated net profit at Rs 333.05 crore for the third quarter ended December 31, led by strong performance of the domestic FMCG business.


The company had posted a net profit of Rs 294.67 crore in October-December of the last fiscal, Dabur India said in a BSE filing.


Total income for the quarter under review was at Rs 2,032.78 crore, as against Rs 1,935.97 crore in the corresponding quarter a year ago.


"While the global macroeconomic environment continues to be challenging and competitive intensity remains high, we have delivered a strong performance during the quarter by efficiently managing the risks and challenges," CEO Sunil Duggal said.


Total expenses of the company were at Rs 1,616.63 crore, as against Rs 1,566.23 crore, up 3.21 percent.


Revenue from consumer care business was up 8.59 percent to Rs 1,696.86 crore in the December quarter as against Rs 1,562.52 crore in the year-ago period.


However, revenue from food business was down 3.83 percent to Rs 210.69 crore as against Rs 219.10 crore. The retail business was also down 9.70 percent to Rs 32.09 crore as against Rs 35.54 crore.


Dabur's international markets also reported growth.


"In local currency terms, Dabur’s business in Egypt grew 46 percent. Sales in GCC rose 20 percent, led by Saudi Arabia which reported 34 percent growth during the quarter. The Sub-Saharan Africa region reported 24 percent growth in local currency," the company said in a statement.


On the outlook, Duggal said:"The medium to long-term prospects, particularly for India, remains robust and we are confident that domestic consumer demand, led by a revival in rural markets, will gain pace in months to come."

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News